Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States.

MLA

Bisognano, John, et al. “Cost-Impact Analysis of Baroreflex Activation Therapy in Chronic Heart Failure Patients in the United States.” BMC Cardiovascular Disorders, vol. 21, no. 1, Mar. 2021, p. 155. EBSCOhost, https://doi.org/10.1186/s12872-021-01958-y.

APA

Bisognano, J., Schneider, J. E., Davies, S., Ohsfeldt, R. L., Galle, E., Stojanovic, I., Deering, T. F., Lindenfeld, J., & Zile, M. R. (2021). Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovascular Disorders, 21(1), 155. https://doi.org/10.1186/s12872-021-01958-y

Chicago

Bisognano, John, John E Schneider, Shawn Davies, Robert L Ohsfeldt, Elizabeth Galle, Ivana Stojanovic, Thomas F Deering, JoAnn Lindenfeld, and Michael R Zile. 2021. “Cost-Impact Analysis of Baroreflex Activation Therapy in Chronic Heart Failure Patients in the United States.” BMC Cardiovascular Disorders 21 (1): 155. doi:10.1186/s12872-021-01958-y.